{"title":"Skin allergy meeting – October 9, 2022, conference report","authors":"Anant D Patil, N. Sharma","doi":"10.25259/ijsa_19_2022","DOIUrl":"https://doi.org/10.25259/ijsa_19_2022","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"41 18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131161139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial intelligence in dermatology – Where do we stand?","authors":"Abhinav Mohta, A. Mohta","doi":"10.25259/ijsa_13_2022","DOIUrl":"https://doi.org/10.25259/ijsa_13_2022","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128976516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chemical-induced vitiligo is a condition where there is a persistent loss of pigment in the skin. For treatment, it is critical to distinguish it from vitiligo vulgaris. We describe a 43-year-old woman who had two depigmented patches, one covering her left cheek and the other her left breast.
{"title":"Mobile cover depigmentation","authors":"P. Srivastava, Amrita Madnani","doi":"10.25259/ijsa_25_2022","DOIUrl":"https://doi.org/10.25259/ijsa_25_2022","url":null,"abstract":"Chemical-induced vitiligo is a condition where there is a persistent loss of pigment in the skin. For treatment, it is critical to distinguish it from vitiligo vulgaris. We describe a 43-year-old woman who had two depigmented patches, one covering her left cheek and the other her left breast.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133132621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study of association of prurigo nodularis and atopy","authors":"A. Rao, M. Tejal","doi":"10.25259/ijsa_24_2022","DOIUrl":"https://doi.org/10.25259/ijsa_24_2022","url":null,"abstract":"","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114350141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hand eczema is a frequent condition that dermatologists commonly encounter. It leads to considerable impact on quality of life (QOL) by significant functional impairment, disruption of work, and discomfort in the working population. The symptoms range from a minor discomfort to a serious debilitating and long-term conditions. Workers engaged in lock making constitute an economically poor section of society. They are exposed to different kinds of allergens, hence are predisposed to develop hand eczema. The aim of this study was to study the impact of hand eczema on the QOL in workers engaged in lock making. A total of 65 workers engaged in lock making and suffering from hand eczema, who visited the out-patient department of dermatology for 6 months, were included in this study. Data on QOL were obtained through a questionnaire devised by Finlay et al. Hand eczema severity index (HECSI) was used to assess the severity of disease. Associations were drawn regarding Dermatology Life Quality Index (DLQI) and HECSI scores with age, sex, duration of disease, number of episodes of illness, and number of sick leaves. Sixty-five patients suffering from hand eczema and engaged in lock making participated in this study, of which 52 (80%) were male and 13 (20%) were female. The commonest age group affected was 36–40 years (41.53%). The most common morphological pattern seen was hyperkeratotic palmar eczema in 50.7% (n = 33) patients followed by chronic dry fissured eczema in 35.3% (n = 23). The mean HECSI score was 19.52 (Standard deviation [SD] = 9.416) and mean DLQI score was 9.92 (SD = 2.426). A significant association of DLQI was seen with duration of disease (P = 0.011), number of episodes of eczema (P = 0.003), and number of sick leaves taken (P = 0.005). Similarly, HECSI score showed significant association with duration of disease (P = 0.002) but not with number of episodes of eczema (P = 0.056). No significant association was found between hand eczema severity and QOL. Being a OPD-based study, it may not truly reflect the community data. Patch test could not be done as workers were poor and could not afford it. Lock makers with hand eczema showed considerable impairment of their QOL. Further, they are more prone to absenteeism from work.
{"title":"The impact of hand eczema severity on quality of life in workers engaged in lock making: A cross-sectional study from tertiary care hospital","authors":"M. Siddiqui, Fariz Sarshar, Ambika Saraswat","doi":"10.25259/ijsa_16_2022","DOIUrl":"https://doi.org/10.25259/ijsa_16_2022","url":null,"abstract":"\u0000\u0000Hand eczema is a frequent condition that dermatologists commonly encounter. It leads to considerable impact on quality of life (QOL) by significant functional impairment, disruption of work, and discomfort in the working population. The symptoms range from a minor discomfort to a serious debilitating and long-term conditions. Workers engaged in lock making constitute an economically poor section of society. They are exposed to different kinds of allergens, hence are predisposed to develop hand eczema. The aim of this study was to study the impact of hand eczema on the QOL in workers engaged in lock making.\u0000\u0000\u0000\u0000A total of 65 workers engaged in lock making and suffering from hand eczema, who visited the out-patient department of dermatology for 6 months, were included in this study. Data on QOL were obtained through a questionnaire devised by Finlay et al. Hand eczema severity index (HECSI) was used to assess the severity of disease. Associations were drawn regarding Dermatology Life Quality Index (DLQI) and HECSI scores with age, sex, duration of disease, number of episodes of illness, and number of sick leaves.\u0000\u0000\u0000\u0000Sixty-five patients suffering from hand eczema and engaged in lock making participated in this study, of which 52 (80%) were male and 13 (20%) were female. The commonest age group affected was 36–40 years (41.53%). The most common morphological pattern seen was hyperkeratotic palmar eczema in 50.7% (n = 33) patients followed by chronic dry fissured eczema in 35.3% (n = 23). The mean HECSI score was 19.52 (Standard deviation [SD] = 9.416) and mean DLQI score was 9.92 (SD = 2.426). A significant association of DLQI was seen with duration of disease (P = 0.011), number of episodes of eczema (P = 0.003), and number of sick leaves taken (P = 0.005). Similarly, HECSI score showed significant association with duration of disease (P = 0.002) but not with number of episodes of eczema (P = 0.056). No significant association was found between hand eczema severity and QOL. Being a OPD-based study, it may not truly reflect the community data. Patch test could not be done as workers were poor and could not afford it.\u0000\u0000\u0000\u0000Lock makers with hand eczema showed considerable impairment of their QOL. Further, they are more prone to absenteeism from work.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132096207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anaphylaxis is a severe, acute, and potentially fatal multi-organ reaction caused by exposure to an allergen. The most involved organ systems are skin, pulmonary, cardiovascular, and gastrointestinal systems, with cutaneous system involvement witnessed in up to 90% of cases. Three commonest reported triggers are food, medicine, and insect venom. It is characterized clinically by wheals and/or angioedema in association with dyspnea, tachypnea, wheezing, tachycardia, vomiting , abdominal pain, diarrhea, clammy skin, confusion, and anxiety. According to the available data, the likelihood of experiencing an episode of anaphylaxis during a lifetime can be expected in up to 2% of population. The incidence of anaphylaxis has been increasing because of the globalization, which has resulted in increased migration of inherent population to distant areas of the world, wider distribution of food and medicines. Furthermore, because of the climate change brought about by industrialization and automation, there has been a noticeable change in the local insect species. People manifesting with any of the three clinical presentations of atopic diathesis (namely, asthma, eczema, and allergic rhinitis) generally have higher chances of experiencing anaphylaxis, and the three most common incriminating triggers include food item, latex rubber, and radio contrast agents. Depending on the patho-physiological mechanism involved, anaphylaxis can be either immunologic, non-immunologic, or idiopathic. The diagnosis of anaphylaxis can largely be made based purely on the presenting sign and symptoms. However, in some rare cases, when it is not possible to make the diagnosis clinically, laboratory investigations are used to supplement or to exclude a specific entity. The standard protocol for managing a case of anaphylaxis includes removal of the trigger, initiation of epinephrine therapy at an earliest, appropriate positioning of the patient to maintain free airway, and hemodynamic balance and call for help for multidisciplinary approach. It is often misdiagnosed owning to the markedly varying clinical presentations, and absence of specific diagnostic laboratory test. Thus, in the present review we have given a comprehensive update to freshen up the knowledge of the physician, to enable them to easily diagnose and manage a suspected case of anaphylaxis, to avoid potential complications and fatalities, and even prevent repeated attacks in some of the cases.
{"title":"Anaphylaxis – A must know for all","authors":"Y. Manchanda, S. Das","doi":"10.25259/ijsa_9_2022","DOIUrl":"https://doi.org/10.25259/ijsa_9_2022","url":null,"abstract":"Anaphylaxis is a severe, acute, and potentially fatal multi-organ reaction caused by exposure to an allergen. The most involved organ systems are skin, pulmonary, cardiovascular, and gastrointestinal systems, with cutaneous system involvement witnessed in up to 90% of cases. Three commonest reported triggers are food, medicine, and insect venom. It is characterized clinically by wheals and/or angioedema in association with dyspnea, tachypnea, wheezing, tachycardia, vomiting , abdominal pain, diarrhea, clammy skin, confusion, and anxiety. According to the available data, the likelihood of experiencing an episode of anaphylaxis during a lifetime can be expected in up to 2% of population. The incidence of anaphylaxis has been increasing because of the globalization, which has resulted in increased migration of inherent population to distant areas of the world, wider distribution of food and medicines. Furthermore, because of the climate change brought about by industrialization and automation, there has been a noticeable change in the local insect species. People manifesting with any of the three clinical presentations of atopic diathesis (namely, asthma, eczema, and allergic rhinitis) generally have higher chances of experiencing anaphylaxis, and the three most common incriminating triggers include food item, latex rubber, and radio contrast agents. Depending on the patho-physiological mechanism involved, anaphylaxis can be either immunologic, non-immunologic, or idiopathic. The diagnosis of anaphylaxis can largely be made based purely on the presenting sign and symptoms. However, in some rare cases, when it is not possible to make the diagnosis clinically, laboratory investigations are used to supplement or to exclude a specific entity. The standard protocol for managing a case of anaphylaxis includes removal of the trigger, initiation of epinephrine therapy at an earliest, appropriate positioning of the patient to maintain free airway, and hemodynamic balance and call for help for multidisciplinary approach. It is often misdiagnosed owning to the markedly varying clinical presentations, and absence of specific diagnostic laboratory test. Thus, in the present review we have given a comprehensive update to freshen up the knowledge of the physician, to enable them to easily diagnose and manage a suspected case of anaphylaxis, to avoid potential complications and fatalities, and even prevent repeated attacks in some of the cases.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124658425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The disease, because of its associated morbidity, mortality, and fast spread, has created panic among all sections of society. Hand washing and hand sanitizers are useful preventive measures against acquisition of SARS-CoV-2. However, overzealous use may be harmful and can cause hand eczema. People with certain occupations have higher risk of hand eczema. In this article, we report six adult patients who developed hand eczema after frequent hand washing and use of hand sanitizers during COVID-19 pandemic. Treatment and outcome of hand eczema in these patients are also discussed.
{"title":"Hand eczema associated with frequent hand washing and use of hand sanitizer during COVID-19 pandemic: A case series","authors":"N. Sharma, Ramanjit Singh, Anant D Patil","doi":"10.25259/ijsa_11_2021","DOIUrl":"https://doi.org/10.25259/ijsa_11_2021","url":null,"abstract":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The disease, because of its associated morbidity, mortality, and fast spread, has created panic among all sections of society. Hand washing and hand sanitizers are useful preventive measures against acquisition of SARS-CoV-2. However, overzealous use may be harmful and can cause hand eczema. People with certain occupations have higher risk of hand eczema. In this article, we report six adult patients who developed hand eczema after frequent hand washing and use of hand sanitizers during COVID-19 pandemic. Treatment and outcome of hand eczema in these patients are also discussed.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122516406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vaishali Atram Dhurve, A. Surjushe, Anand Saraswat, Neha Baheti Mundada
Nicolau’s syndrome, also known as embolia cutis medicamentosa or livedo-like dermatitis, is an uncommon rare cutaneous adverse reaction occurring at the site of intramuscular, intra-articular, or rarely subcutaneous injection of particular drugs, leading to necrosis of skin and underlying tissues. We, hereby, report two fatal cases of this syndrome after taking intramuscular injection of diclofenac sodium.
{"title":"Nicolau’s syndrome following intramuscular administration of Diclofenac sodium","authors":"Vaishali Atram Dhurve, A. Surjushe, Anand Saraswat, Neha Baheti Mundada","doi":"10.25259/ijsa_13_2021","DOIUrl":"https://doi.org/10.25259/ijsa_13_2021","url":null,"abstract":"Nicolau’s syndrome, also known as embolia cutis medicamentosa or livedo-like dermatitis, is an uncommon rare cutaneous adverse reaction occurring at the site of intramuscular, intra-articular, or rarely subcutaneous injection of particular drugs, leading to necrosis of skin and underlying tissues. We, hereby, report two fatal cases of this syndrome after taking intramuscular injection of diclofenac sodium.","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"2015 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127661623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Shah, A. Choudhary, Deval Mistry, N. Jangid, Shikha R. Shah, Shruti Kamat, G. Deshmukh, D. Dhoot, Hanmant Barkate
In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult. Eighty patients with chronic spontaneous urticaria (CSU) were randomized to receive either bilastine or fexofenadine (40 in each group). Patients were started on conventional dose of either drug (bilastine 20 mg or fexofenadine 180 mg) for the first 2 weeks. Those patients who remained symptomatic after 2 weeks (UAS ≥ 7) were given double dose of bilastine (20 mg BD) or fexofenadine (180 mg BD), respectively, for another 2 weeks. Control of urticaria was assessed by evaluating UAS score. Patients’ quality of life was assessed by CU-Q2oL questionnaire. Safety was evaluated by analyzing the adverse events (AEs) reported by the patients. Seventy-four patients completed the study. Forty-one patients (bilastine – 23 and fexofenadine – 18) achieved adequate control of urticaria (UAS ≤ 6) at week 2. Out of 33 patients who were given high dose of bilastine or fexofenadine, 17 patients (bilastine – 9 and fexofenadine – 8) achieved adequate control of urticaria at week 4. Bilastine was associated with significant improvement in quality of life of patients compared to fexofenadine (32.38 ± 5.83 vs. 38.71 ± 5.92.; P < 0.005). Thirteen patients (six in bilastine group and seven in fexofenadine group) reported one or more AEs with sedation being the most common side effect. Updosing of bilastine provided relief from urticaria symptoms, improved quality of life in the majority of the patients without compromising somnolence or safety. Bilastine was associated with improved quality of life and less sedation compared to fexofenadine.
{"title":"The effectiveness of bilastine and fexofenadine updosing in the management of chronic spontaneous urticaria","authors":"B. Shah, A. Choudhary, Deval Mistry, N. Jangid, Shikha R. Shah, Shruti Kamat, G. Deshmukh, D. Dhoot, Hanmant Barkate","doi":"10.25259/ijsa_3_2021","DOIUrl":"https://doi.org/10.25259/ijsa_3_2021","url":null,"abstract":"\u0000\u0000In patients not responding to standard dosages of second-generation antihistamines (SGAHs), updosing up to 4-fold is recommended. Even though SGAHs are safe, the concerns regarding their safety after updosing still remain and the studies directly comparing the updosing of different SGAHs are lacking thus making the choice of drug difficult.\u0000\u0000\u0000\u0000Eighty patients with chronic spontaneous urticaria (CSU) were randomized to receive either bilastine or fexofenadine (40 in each group). Patients were started on conventional dose of either drug (bilastine 20 mg or fexofenadine 180 mg) for the first 2 weeks. Those patients who remained symptomatic after 2 weeks (UAS ≥ 7) were given double dose of bilastine (20 mg BD) or fexofenadine (180 mg BD), respectively, for another 2 weeks. Control of urticaria was assessed by evaluating UAS score. Patients’ quality of life was assessed by CU-Q2oL questionnaire. Safety was evaluated by analyzing the adverse events (AEs) reported by the patients.\u0000\u0000\u0000\u0000Seventy-four patients completed the study. Forty-one patients (bilastine – 23 and fexofenadine – 18) achieved adequate control of urticaria (UAS ≤ 6) at week 2. Out of 33 patients who were given high dose of bilastine or fexofenadine, 17 patients (bilastine – 9 and fexofenadine – 8) achieved adequate control of urticaria at week 4. Bilastine was associated with significant improvement in quality of life of patients compared to fexofenadine (32.38 ± 5.83 vs. 38.71 ± 5.92.; P < 0.005). Thirteen patients (six in bilastine group and seven in fexofenadine group) reported one or more AEs with sedation being the most common side effect.\u0000\u0000\u0000\u0000Updosing of bilastine provided relief from urticaria symptoms, improved quality of life in the majority of the patients without compromising somnolence or safety. Bilastine was associated with improved quality of life and less sedation compared to fexofenadine.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"188 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114743397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to assess and evaluate Vitamin D levels in CSU cases and compare with controls and to determine a correlation if any between Vitamin D levels and severity of CSU. A hospital-based case–control study of 130 cases and 130 controls was done. The assessment of severity of CSU was done using Urticaria Activity Score (UAS7). Laboratory investigations including Vitamin D levels were done in both groups. Mean serum Vitamin D levels in cases and controls were 14.29 ng/ml and 28.8 ng/ml, respectively. Ninety-nine (76.2%) cases had deficient levels, 25 had insufficient levels, and six had normal levels. In controls, 63 had normal serum Vitamin D levels, 46 had insufficient, and 21 (16.1%) had deficient levels (t = −13.2340; P < 0.001). Cases with Vitamin D levels <10 ng/ml, 10–20 ng/ml, 20–30 ng/ml, and >30 ng/ml had mean UAS score of 18, 15.17, 7.28, and 6.67, respectively. In this study, deficient Vitamin D levels were more commonly seen in cases as compared to controls and correlated inversely with the severity of disease as measured by UAS7. Vitamin D might be one among the multiple factors involved in etiopathogenesis/exacerbation of CSU or may be an outcome of the disease process. Adding Vitamin D supplements may improve clinical outcome in patients of CSU and reduce use of corticosteroids and immunosuppressive.
{"title":"Hospital-based cross-sectional study to assess Vitamin D levels in patients of chronic spontaneous urticaria and its relation to severity of disease activity","authors":"Yashshavani Dass, D. Dogra, N. Dogra","doi":"10.25259/ijsa_11_2022","DOIUrl":"https://doi.org/10.25259/ijsa_11_2022","url":null,"abstract":"\u0000\u0000The aim of this study was to assess and evaluate Vitamin D levels in CSU cases and compare with controls and to determine a correlation if any between Vitamin D levels and severity of CSU.\u0000\u0000\u0000\u0000A hospital-based case–control study of 130 cases and 130 controls was done. The assessment of severity of CSU was done using Urticaria Activity Score (UAS7). Laboratory investigations including Vitamin D levels were done in both groups.\u0000\u0000\u0000\u0000Mean serum Vitamin D levels in cases and controls were 14.29 ng/ml and 28.8 ng/ml, respectively. Ninety-nine (76.2%) cases had deficient levels, 25 had insufficient levels, and six had normal levels. In controls, 63 had normal serum Vitamin D levels, 46 had insufficient, and 21 (16.1%) had deficient levels (t = −13.2340; P < 0.001). Cases with Vitamin D levels <10 ng/ml, 10–20 ng/ml, 20–30 ng/ml, and >30 ng/ml had mean UAS score of 18, 15.17, 7.28, and 6.67, respectively.\u0000\u0000\u0000\u0000In this study, deficient Vitamin D levels were more commonly seen in cases as compared to controls and correlated inversely with the severity of disease as measured by UAS7. Vitamin D might be one among the multiple factors involved in etiopathogenesis/exacerbation of CSU or may be an outcome of the disease process. Adding Vitamin D supplements may improve clinical outcome in patients of CSU and reduce use of corticosteroids and immunosuppressive.\u0000","PeriodicalId":340475,"journal":{"name":"Indian Journal of Skin Allergy","volume":"333 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131656509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：